Immunovant Inc (NASDAQ:IMVT) has a beta value of 0.78 and has seen 3.07 million shares traded in the last trading session. The company, currently valued at $2.46B, closed the last trade at $14.46 per share which meant it lost -$0.69 on the day or -4.55% during that session. The IMVT stock price is -138.38% off its 52-week high price of $34.47 and 12.03% above the 52-week low of $12.72. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.24 million shares traded. The 3-month trading volume is 1.78 million shares.
The consensus among analysts is that Immunovant Inc (IMVT) is Buy stock at the moment, with a recommendation rating of 1.14. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 20 have rated it as a Hold, with 13 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.72.
Immunovant Inc (NASDAQ:IMVT) trade information
Sporting -4.55% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the IMVT stock price touched $14.46 or saw a rise of 8.37%. Year-to-date, Immunovant Inc shares have moved -41.62%, while the 5-day performance has seen it change -1.50%. Over the past 30 days, the shares of Immunovant Inc (NASDAQ:IMVT) have changed -26.56%. Short interest in the company has seen 19.68 million shares shorted with days to cover at 10.43.
Wall Street analysts have a consensus price target for the stock at $49, which means that the shares’ value could jump 70.49% from current levels. The projected low price target is $5.0 while the price target rests at a high of $57.0. In that case, then, we find that the current price level is -294.19% off the targeted high while a plunge would see the stock lose 65.42% from current levels.
Immunovant Inc (IMVT) estimates and forecasts
The company’s shares have lost -50.43% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
Earnings growth for 2025 is a modest -49.30% while over the next 5 years, the company’s earnings are expected to decrease by -20.54%.
IMVT Dividends
Immunovant Inc is expected to release its next earnings report on 2025-May-29 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Immunovant Inc (NASDAQ:IMVT)’s Major holders
Insiders own 58.59% of the company shares, while shares held by institutions stand at 49.64% with a share float percentage of 119.86%. Investors are also buoyed by the number of investors in a company, with Immunovant Inc having a total of 267.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 10.48 million shares worth more than $276.77 million. As of 2024-06-30, FMR LLC held 7.1765% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.51 million shares as of 2024-06-30. The firm’s total holdings are worth over $171.86 million and represent 4.4561% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Feb 28, 2025 , the former fund manager holds about 2.39% shares in the company for having 4.06 shares of worth $58.67 million while later fund manager owns 2.08 shares of worth $30.03 million as of Dec 31, 2024 , which makes it owner of about 1.22% of company’s outstanding stock.
